Matricelf Named Most Innovative Company of 2026 at Advanced Therapies Week in San Diego

Rhea-AI Summary

Matricelf (MTRLF) was named Most Innovative Company of 2026 at Advanced Therapies Week in San Diego on March 2, 2026, winning the Innovation Exchange Award among roughly 1,800 participants and 600 global drug developers.

The company highlighted rapid progress toward initiating a first-in-human clinical study in paralyzed spinal cord injury patients in the coming months, and said the award expands exposure to global investors and potential partners.

Winner of the Innovation Exchange Award among 1,800 participants and 600 global drug developers; advancing toward first-in-human clinical study in spinal cord injury patients

SAN DIEGO and NESS ZIONA, Israel, March 2, 2026 /PRNewswire/ -- Matricelf Ltd. (TASE: MTLF), a biotechnology company developing personalized regenerative therapies, today announced that it was awarded 1st place at the prestigious Innovation Exchange Award and named the Most Innovative Company of 2026 at Advanced Therapies Week (ATW26), held in San Diego, California.

Advanced Therapies Week is considered one of the leading global conferences in the field of advanced therapies and regenerative medicine, convening biotechnology and pharmaceutical companies, researchers, investors, and key opinion leaders from around the world. This year's conference hosted more than 1,800 participants, including approximately 600 drug developers and global industry leaders.

Matricelf was selected by a professional judging committee for its groundbreaking approach to spinal cord injury repair and its rapid progress toward clinical-stage development. According to the competition organizers, Matricelf's nomination stood out as a compelling example of a technology that demonstrates both significant potential patient impact and strong commercial promise.

The company outperformed hundreds of biotechnology and cell therapy companies from the United States and Europe. The award provides strategic exposure and access to leading global investors and potential partners, positioning Matricelf at the forefront of innovation in advanced therapies.

"This recognition as the most innovative company among hundreds of leading cell therapy developers worldwide is a defining moment for Matricelf and for Israeli biotechnology," said Gil Hakim, CEO of Matricelf. "It represents strong international validation of the technology originally developed at Tel Aviv University under the leadership of Prof. Tal Dvir, the company CSO, and now fully developed and implemented at our facilities in Ness Ziona. This momentum strengthens us as we advance toward our key 2026 milestone: initiating a first-of-its-kind clinical study in paralyzed spinal cord injury patients in the coming months, with the goal of bringing hope to millions of individuals worldwide."

About Matricelf

Matricelf Ltd. is a regenerative medicine company focused on developing personalized, autologous cell-based therapies for spinal cord injury. Leveraging proprietary hydrogel technology and advanced tissue engineering, Matricelf aims to restore function in patients suffering from paralysis by creating patient-specific neural tissue implants. The company's technology originated at Tel Aviv University and is being further developed at its facilities in Ness Ziona, Israel.

CONTACT INFO:
Gil Hakim
CEO
Matricelf
Tel: +972-52-5263351
GIL@MATRICELF.COM

 

View original content:https://www.prnewswire.com/news-releases/matricelf-named-most-innovative-company-of-2026-at-advanced-therapies-week-in-san-diego-302700791.html

SOURCE Matricelf Ltd.

FAQ

What award did Matricelf (MTRLF) win at Advanced Therapies Week on March 2, 2026?

Matricelf won the Innovation Exchange Award and was named Most Innovative Company of 2026. According to the company, the prize was selected from about 1,800 participants and roughly 600 global drug developers, providing strategic exposure to investors and partners.

Where and when did Matricelf announce its ATW26 recognition for MTRLF?

Matricelf announced the ATW26 recognition in San Diego on March 2, 2026. According to the company, the award ceremony occurred at Advanced Therapies Week, a global conference hosting about 1,800 participants and 600 drug developers.

How does the ATW26 award affect Matricelf's (MTRLF) investor visibility?

The award increases Matricelf's strategic exposure to global investors and potential partners. According to the company, winning among hundreds of biotech and cell therapy firms enhances international validation and visibility ahead of clinical milestones.

When will Matricelf (MTRLF) begin its first-in-human spinal cord injury study?

Matricelf plans to initiate a first-in-human clinical study in paralyzed spinal cord injury patients in the coming months of 2026. According to the company, this is a key 2026 milestone as the program advances toward clinical-stage development.

Why did Matricelf (MTRLF) receive the Most Innovative Company award at ATW26?

The award recognized Matricelf's approach to spinal cord injury repair and clinical progress. According to the company, judges cited potential patient impact and commercial promise as reasons for selecting Matricelf from many entrants.